|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
41,270,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$ - $ |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Tyra Biosciences is an oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Co. is focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor, or FGFR family. Co.'s lead product candidate, TYRA-300, is designed to selectively inhibit Fibroblast Growth Factor Receptor3, with an initial focus on patients with bladder cancer. In addition, Co. has pipeline development programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during Transfection kinase, and FGFR4-related cancers.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
8,253 |
221,691 |
456,290 |
785,314 |
Total Sell Value |
$165,635 |
$3,766,874 |
$7,701,881 |
$12,216,507 |
Total People Sold |
1 |
2 |
2 |
3 |
Total Sell Transactions |
5 |
15 |
38 |
53 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Tada Hiroomi |
Chief Medical Officer |
|
2024-03-15 |
4 |
A |
$6.58 |
$12,947 |
D/D |
1,968 |
86,435 |
|
- |
|
Harris Todd |
President and CEO |
|
2024-03-15 |
4 |
A |
$6.58 |
$12,369 |
D/D |
1,880 |
1,504,577 |
|
- |
|
Fuhrman Alan |
Chief Financial Officer |
|
2024-03-15 |
4 |
A |
$12.48 |
$11,629 |
D/D |
932 |
2,395 |
|
- |
|
Bensen Daniel |
Chief Operating Officer |
|
2024-03-11 |
4 |
AS |
$20.00 |
$4,000 |
D/D |
(200) |
431,683 |
|
- |
|
Bensen Daniel |
Chief Operating Officer |
|
2024-03-07 |
4 |
AS |
$20.00 |
$1,360 |
D/D |
(68) |
431,883 |
|
- |
|
Bensen Daniel |
Chief Operating Officer |
|
2024-03-06 |
4 |
AS |
$20.09 |
$34,819 |
D/D |
(1,733) |
431,951 |
|
- |
|
Bensen Daniel |
Chief Operating Officer |
|
2024-03-05 |
4 |
AS |
$20.02 |
$23,802 |
D/D |
(1,189) |
433,684 |
|
- |
|
Bensen Daniel |
Chief Operating Officer |
|
2024-03-04 |
4 |
AS |
$20.08 |
$101,654 |
D/D |
(5,063) |
434,873 |
|
- |
|
Bensen Daniel |
Chief Operating Officer |
|
2024-03-01 |
4 |
AS |
$20.04 |
$58,112 |
D/D |
(2,900) |
439,936 |
|
- |
|
Bensen Daniel |
Chief Operating Officer |
|
2024-02-29 |
4 |
AS |
$20.00 |
$41,003 |
D/D |
(2,050) |
442,836 |
|
- |
|
Bensen Daniel |
Chief Operating Officer |
|
2024-02-28 |
4 |
AS |
$20.13 |
$117,729 |
D/D |
(5,849) |
444,886 |
|
- |
|
Bensen Daniel |
Chief Operating Officer |
|
2024-02-27 |
4 |
AS |
$20.00 |
$14,900 |
D/D |
(745) |
450,735 |
|
- |
|
Bensen Daniel |
Chief Operating Officer |
|
2024-02-12 |
4 |
AS |
$20.00 |
$30,020 |
D/D |
(1,501) |
451,480 |
|
- |
|
Bensen Daniel |
Chief Operating Officer |
|
2024-02-07 |
4 |
AS |
$18.09 |
$173,466 |
D/D |
(9,587) |
452,981 |
|
- |
|
Shah Rajeev M. |
Director |
|
2024-02-06 |
4 |
A |
$13.01 |
$41,373,817 |
I/I |
3,180,155 |
8,477,275 |
|
- |
|
Davis Aaron I. |
See Remarks |
|
2024-02-06 |
4 |
A |
$13.01 |
$824,990 |
I/I |
63,412 |
85,939 |
|
- |
|
Bensen Daniel |
Chief Operating Officer |
|
2024-02-06 |
4 |
AS |
$18.09 |
$278,827 |
D/D |
(15,413) |
462,568 |
|
- |
|
Harris Todd |
President and CEO |
|
2024-02-05 |
4 |
AS |
$16.97 |
$234,430 |
D/D |
(13,817) |
1,502,697 |
|
- |
|
Harris Todd |
President and CEO |
|
2024-02-02 |
4 |
AS |
$16.45 |
$1,421,655 |
D/D |
(86,183) |
1,516,514 |
|
- |
|
Bensen Daniel |
Chief Operating Officer |
|
2024-02-02 |
4 |
AS |
$16.31 |
$1,231,097 |
D/D |
(75,393) |
477,981 |
|
- |
|
Bensen Daniel |
Chief Operating Officer |
|
2024-02-02 |
4 |
OE |
$0.61 |
$15,490 |
D/D |
25,393 |
553,374 |
|
- |
|
Harris Todd |
President and CEO |
|
2023-09-15 |
4 |
A |
$6.58 |
$9,349 |
D/D |
1,421 |
1,602,697 |
|
- |
|
Tada Hiroomi |
Chief Medical Officer |
|
2023-09-15 |
4 |
A |
$6.58 |
$8,796 |
D/D |
1,337 |
84,467 |
|
- |
|
Fuhrman Alan |
Chief Financial Officer |
|
2023-09-15 |
4 |
A |
$12.50 |
$18,293 |
D/D |
1,463 |
1,463 |
|
- |
|
Bensen Daniel |
Chief Operating Officer |
|
2023-07-21 |
4 |
AS |
$16.01 |
$62,428 |
D/D |
(3,900) |
527,981 |
|
- |
|
135 Records found
|
|
Page 1 of 6 |
|
|